COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of Thymoglobulin and Tacrolimus in Liver Transplant (thymo)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00564538
Recruitment Status : Unknown
Verified November 2007 by University of Nebraska.
Recruitment status was:  Enrolling by invitation
First Posted : November 28, 2007
Last Update Posted : November 28, 2007
Genzyme, a Sanofi Company
Information provided by:
University of Nebraska

Brief Summary:
The purpose of this study is to compare kidney function, long term patient and graft survival, and incidence of acute rejection in liver transplant recipients between one group receiving thymoglobulin induction and delayed initiation of tacrolimus and another group of liver transplant recipients having immediate administration of tacrolimus without any induction immunosuppression.

Condition or disease Intervention/treatment Phase
Liver Transplantation Liver Disease Immunosuppression Drug: anti-thymocyte globulin (rabbit) Drug: tacrolimus Phase 4

Detailed Description:
Renal insufficiency following liver transplantation in adult recipients is a major cause of morbidity and a major contributor to mortality. One of the key factors contributing to this renal dysfunction is the use of calcineurin inhibitors. There is some evidence to suggest that the first 7-10 days following liver transplantation are crucial in terms of renal function and the ability to avoid the use of nephrotoxic agents such as calcineurin inhibitors may have a significant impact on long-term outcome.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function
Study Start Date : December 2007
Estimated Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Tacrolimus

Arm Intervention/treatment
Experimental: 1
Patients in arm 1 will receive induction with thymoglobulin at time of transplant with delayed initiation of tacrolimus
Drug: anti-thymocyte globulin (rabbit)
1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
Other Name: thymoglobulin

Active Comparator: 2
patients in arm 2 will not receive thymo induction at time of transplant and will have immediate initiation of tacrolimus
Drug: tacrolimus
Tacrolimus will be administered orally on post op day #1 as per standard of care.
Other Name: prograf

Primary Outcome Measures :
  1. Evaluation of renal function via Glo-Fil nuclear medicine scan and laboratory parameters [ Time Frame: Post operative day #1, month 6 and month 12 ]

Secondary Outcome Measures :
  1. patient and graft survival, incidence of acute rejection, incidence of active CMV disease, incidence of other infections, any adverse events or serious adverse events associated with the use of thymo induction therapy [ Time Frame: post op days 1-6, months 3,6, 9, and 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary liver transplant recipient with Model for End Stage Liver Disease (MELD) criteria documentation
  • Over 18 years of age
  • Signed informed consent form
  • if female of childbearing potential: Must not be lactating Must have negative serum pregnancy test on study day 0 Must have agreed on a reliable and acceptable form of contraception during the study
  • sexually active males must be practicing an acceptable form of contraception

Exclusion Criteria:

  • Multiple organ transplants
  • Prior solid organ or bone marrow transplant recipients
  • Fulminant hepatic failure
  • Status 1 transplants
  • Liver transplant candidates with greater than 6 weeks of dialysis
  • Patients who in the opinion of the Investigator are not eligible for thymo induction at the time of transplant
  • Recipients of investigational therapy within 90 days prior to transplant
  • Know contraindication to administration of rabbit anti-thymocyte globulin
  • Patients whose medical condition is such that the physician feels it would not be in their best interest to participate in the study
  • Patients who are unwilling to have a Glofil nuclear medicine scan at specified time points
  • History of malignancy within 5 years with the exception of:
  • Adequately treated localized squamous or basal cell carcinoma of the skin without evidence of recurrence, and /or
  • Hepatocellular carcinoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00564538

Layout table for location information
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Sponsors and Collaborators
University of Nebraska
Genzyme, a Sanofi Company
Layout table for investigator information
Principal Investigator: Wendy Grant, MD University of Nebraska
1. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, JM. N. Chronic renal failure following liver transplantation: a retrospective analysis Transplantation 1998; 66 (1): 59. 2. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic lvier transplantation (OLTX) using calcineurin-based immunotherapy. Transplantation 2001; 72: 1934. 3. Moreno JM, Cuervas-Mons V, Rubio E, et al. Chronic renal dysfunction after liver transplantation in adult patients: prevelance, risk factors, and impact on mortality. Transplant Proc 2003; 35 (5): 1907.

Layout table for additonal information Identifier: NCT00564538    
Other Study ID Numbers: 424-07
First Posted: November 28, 2007    Key Record Dates
Last Update Posted: November 28, 2007
Last Verified: November 2007
Keywords provided by University of Nebraska:
liver transplant
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Digestive System Diseases
Antilymphocyte Serum
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action